Flavia Lo Castro's research while affiliated with Università degli Studi di Modena e Reggio Emilia and other places

Publications (12)

Article
Full-text available
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic migraine (CM). Despite this, some aspects of its mechanism of action are still a matter of debate, and the precise magnitude of BT-A effects needs to be completely elucidated. BT-A acts primarily upon trigeminal and cervical nerve endings, by inhibiti...
Chapter
The use of biological drugs has significantly increased over the past decades and has allowed for the treatment of many life-threatening and chronic diseases. The patent expiration of biological innovative medicines enables copies of these drugs called biosimilars. The availability of biosimilars enhances competition, with the potential to improve...
Article
Full-text available
The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of trigeminal excitability. Additionally, clinical data have suggested that an endocannabinoid defici...
Article
Background Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the pres...
Article
Full-text available
Background Neurosteroids affect the balance between neuroexcitation and neuroinhibition but have been little studied in migraine. We compared the serum levels of pregnenolone sulfate, pregnanolone and estradiol in women with menstrually-related migraine and controls and analysed if a correlation existed between the levels of the three hormones and...
Article
Full-text available
Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, D...
Article
Full-text available
Objective To explore the effectiveness and safety of 3 oral cannabinoid preparations (FM2®, Bedrocan® and Bediol®) in the treatment of chronic migraine. Design Retrospective, cohort study. Subjects Patients with chronic migraine who received FM2®, Bedrocan® or Bediol® daily for the off-label treatment of their headache, up to 6 months. Methods T...
Article
Full-text available
Objective Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache. Material and methods This was a retros...
Article
Background: Erenumab is a monoclonal antibody blocking the calcitonin gene-related peptide receptor, which has been approved for the preventive treatment of chronic migraine (CM). The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting,...
Article
Full-text available
Introduction: Interest is growing in the role of pituitary adenylate cyclase-activating polypeptide (PACAP) and its specific PAC1 receptor in migraine and in their antagonism as a strategy for migraine prevention. Areas covered: We discuss and critically evaluate (i) the evidence of the role of PACAP in migraine pathophysiology and (ii) the firs...
Article
Full-text available
Background Reduced blood or cerebrospinal fluid levels of allopregnanolone are involved in menstrual cycle-linked CNS disorders, such as catamenial epilepsy. This condition, like menstrually-related migraine, is characterized by severe, treatment-resistant attacks. We explored whether there were differences in allopregnanolone, progesterone and tes...
Article
Full-text available
The aim of this pilot study was to analyze the serum proteomic profile of women suffering from menstrual-related migraine (MM group, n = 15) and migraine in post-menopause (PM group, n = 15) in comparison with non-headache control females (C group, n = 15). Serum samples were subjected to two-dimensional gel electrophoresis (2-DE) followed by mass...

Citations

... These results indicate that eCBs play an important role in modulating inflammation and nociception [106]. To date, there are increased number of studies investigating the role of modulation of eCB system in the animal models of migraine or TBI [107], and several clinical trials have also been performed using synthetic cannabinoids and phytocannabinoids for migraineurs [108] and TBI patients [109]. ...
... Two studies described patients undergoing planned and unplanned treatment breaks [47,68], ten explicitly described a planned break in treatment with the anti-CGRP-mAb [52,62, 73,80,83,84,92,95,101,122], and six reported an unplanned break in treatment [42,45,58,66,74,96]. In contrast, 65 of these 83 real-world studies did not have study periods that allowed for analysis of a treatment break or did not describe a treatment break at all. ...
... As gepants are strong CYP3A4 inducers, their use in concomitance with other CYP3A4 inducers, CYP3A4 inhibitors and OATP inhibitors should be carefully evaluated [44]. Moreover, gepants should be avoided during pregnancy [45]. ...
... A total of 12 studies with 1,980 participants were included. The included studies were seven peer-reviewed publications (19)(20)(21)(22)(23)(24)(25) and five conference abstracts, including two case reports (26,27), one case series (28), one retrospective chart review (29), and one randomized control trial (30). The seven peer-reviewed publications were retrospective cohort study (22), retrospective analysis of medical charts of migraine patients who used MC (19,25) or analysis of MC Application (App) (20,21) and online surveys (23,24). ...
... In the cohort reported by Cheng et al. the prevalence of daily headache (or 'zero headache free days') was 77/170 (45%), and in contrast to our study did not find any association between patients reporting no headache free days and response to erenumab at 3 or 6 months [8]. Whilst other studies have not specifically reported with respect to daily headache, they have generally shown that non-responders had greater numbers of headache days [11,14], although Barbanti et al. found that a greater number of headache days was associated with positive erenumab response in their chronic migraine group [15]. This observation merits further investigation and we would encourage that this metric be included in future studies of response to erenumab. ...
... Serum allopregnanolone levels are associated with the incidence of psychiatric disorders and chronic pain in military veterans [38]. Similarly, the occurrence of postmenopausal migraine in depressed women is also associated with low allopregnanolone levels and normal progesterone and testosterone levels [39]. In contrast, patients with bipolar disorder and a history of cannabis use have higher serum pregnanolone levels, lower allopregnanolone levels, a higher pregnanolone-toallopregnanolone ratio, and a lower pregnenolone-to-pregnanolone ratio compared with patients with no history of cannabis use. ...
... In addition to evidence from RCTs, there is also evidence from real-world studies suggesting that CGRP-mAbs are highly effective even in the absence of prior detoxification in individuals with medication overuse [31,56] and that the response to CGRP-mAbs does not depend on detoxification [57,58]. ...
... To abolish pain, the anti-migraine drugs are presently designed to cause a reversal of the vasodilation process in the outer cerebral, and inter-cranial veins. Besides, there exists a thriving interest in learning the role of pituitary adenylate cyclase-activating peptide (PACAP 38) and its affinities with the nociceptor, procaspase activating compound-1 receptor (PAC1-R) toward the deterrence of migraine (Rustichelli et al. 2020). PACAP-38 is a glucagon/secretin, multifunctional vasodilatory peptide encoded by the gene APCYAP1, while PAC1-R is a G-protein coupled receptor (Denes et al. 2019). ...
... **; p < 0.01 (paired t-test) of dural afferent neurons. We used young male rats to minimize the variables mediated by hormones and/or neurosteroids that fluctuate due to the menstrual cycle, such as progesterone, pregnenolone, and allopregnanolone, as the serum levels of these compounds are associated with chronic headache disorders [38,39]. It has been shown that migraine prevalence peaks in females' post-puberty [40,41] and that there are both quantitative and qualitative differences in the IM-induced sensitization of dural afferents [26]. ...
... However, in the PM group, upregulation of transthyretin along with the other deregulated proteins such as tetranectin, apolipoprotein A-IV alpha-1-antitrypsin, and haptoglobin was observed. In addition, prothrombin, serum amyloid P-component, Ig kappa chain C region, apolipoprotein A-I, serum amyloid A-4 protein, the regulators of vascular integrity and inflammatory proteins, were also found to be dysregulated in both MM and PM groups [119]. These proteomic studies have been summarized in Table 7. ...